Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 PK, safety and preliminary efficacy study of Peginterferon alfa-2b in hydroxyurea-resistant or -intolerant essential thrombocythemia
ChiCTR2400088120Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b in thrombocythemia (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Pharmacokinetic profiles and dose-exposure-effect relationship at Week 96. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on ChiCTR2400088120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088120.